Videos

Despite effective vaccines and other prevention and treatment modalities, hepatitis B remains a global health challenge. “It’s not for the lack of available tools,” says professor and hepatologist H. Nina Kim, MD, MSc.

“Patients deserve more than just viral suppression,” said Harmony Garges, MD, chief medical officer of ViiV Healthcare.

A researcher who presented at CROI discusses this prolonged and debilitating condition.

A clinician presenting at CROI discusses the phenomenon and offers insights and considerations for treating patients who are dealing with this.

“We should test everybody,” said Charles Béguelin, noting that the vast majority of hepatitis D infections go undetected.

“One size never fits all,” says hepatologist Anna Suk-Fong Lok, MD, emphasizing the need to tailor hepatitis B treatment to fit the patient.

A clinician offers insights on the initial conversations around learning to treat a chronic disease and the importance behind getting patients started down the right treatment path in the early days following a diagnosis.

The Conference on Retroviruses and Opportunistic Infections (CROI) begins today and SARS-CoV-2 has developed into a sustained topic at this annual conference.

A prominent researcher offers some insights on this emerging fungal infection.

This live-attenuated investigational vaccine was developed by Codagenix, which uses its codon de-optimization platform for its candidates.

Clostridioides difficile (CDI) and recurrence can create a tremendous burden on patients’ quality of life as well as become a financial burden to individual healthcare systems thus creating downstream costs for individual hospitals.

A new Infectious Diseases Society of America (IDSA) board member and vice president offers some insights on the leadership’s goals and direction for 2023.

One clinician offers some insights on the RSV surge witnessed last year and the prospective benefits of having a maternal vaccine to protect newborns from this virus.

A look back on some of the significant discussions with clinicians, researchers, and infectious disease stakeholders.

The New Drug Application (NDA) for the company’s investigational therapy, Olorofim, looks to serve an unmet medical need in this treatment space.

The Wistar Institute’s research on DNA-encoded SARs-CoV-2 monoclonal antibodies (DMAbs) allowed it to advance to clinical trials. One researcher explains how it differs from the mRNA platform.

Dr. Elizabeth Garner speculates the FDA approval of RBX2660 for recurrent C difficile infection will pave the way for more restorative microbiome therapies.

Ferring Chief Scientific Officer Dr. Elizabeth Garner explains the FDA approval of recurrent C diff treatment RBX2660 provides more than a treatment option, it’s a promise of safety and standardization.

In episode 1 of this short video series, a clinician discusses what types of patients are best suited for inpatient or outpatient care for these infections.

Two patients at a hospital in Australia were administered Thin Film Freezing Voriconazole Inhalation Powder (TFF VORI), which showed treatment efficacy for both patients.

Dr. Tosin Goje explains the promise of ibrexafungerp for clearing yeast infection and improving quality of life for these patients.

A clinician offers his perspective on what he sees as a clinician and trial investigator in terms of what is in the pipeline and both the encouraging data and uncertainty in therapy development overall.

Young women who binge drink, and especially those who use multiple substances, had a higher risk of COVID-19 infection and mental health complications.

One clinician discusses strategies in how his institution minimizes the wide spectrum approach to antibiotics as well as tries to prevent potential complications.

An ICU hospitalist talks about his criteria and the treatment protocols for these cases.

Dynavax reported results from its phase 1 study looking at its (Tdap-1018 CpG Adjuvanted) Tetanus/Diphtheria/Pertussis booster vaccine.

In episode 1 of this short video series, a clinician discusses his experience in what his institution is seeing as well as how they handle their treatment protocol and stewardship where possible.

Studies suggest young women’s substance use is catching up to men's. Tammy Chung, PhD, examined whether this was exacerbated by the COVID-19 pandemic.